{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:59:30Z","timestamp":1761663570260},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,3]],"date-time":"2016-12-03T00:00:00Z","timestamp":1480723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","jfma-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.jfma.2016.11.014","type":"journal-article","created":{"date-parts":[[2016,12,26]],"date-time":"2016-12-26T16:30:45Z","timestamp":1482769845000},"page":"295-299","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response"],"prefix":"10.1016","volume":"116","author":[{"given":"Chun-Ming","family":"Hong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiou-Hwei","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Jer","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2016.11.014_bib1","series-title":"Hepatitis C key facts","author":"World Health Organization","year":"2013"},{"key":"10.1016\/j.jfma.2016.11.014_bib2","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2016.11.014_bib3","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment Web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2016.11.014_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.vhri.2013.08.001","article-title":"Estimating the incidence and prevalence of chronic hepatitis C infection in Taiwan using back projection","volume":"3","author":"McEwan","year":"2014","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.jfma.2016.11.014_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jfma.2015.06.012","article-title":"Hepatitis C virus infection in Taiwan: past, present, and future","volume":"115","author":"Kao","year":"2016","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2016.11.014_bib6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/jmv.2001","article-title":"Changing prevalence of hepatitis C virus genotypes: molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan","volume":"65","author":"Yu","year":"2001","journal-title":"J Med Virol"},{"key":"10.1016\/j.jfma.2016.11.014_bib7","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4254\/wjh.v8.i2.92","article-title":"Chronic hepatitis C: this and the new era of treatment","volume":"8","author":"Bertino","year":"2016","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jfma.2016.11.014_bib8","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jfma.2016.11.014_bib9","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1128\/AAC.01186-12","article-title":"Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032)","volume":"56","author":"McPhee","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jfma.2016.11.014_bib10","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2016.11.014_bib11","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","article-title":"Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection","volume":"59","author":"Kumada","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2016.11.014_bib12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/bioinformatics\/bth485","article-title":"The Los Alamos hepatitis C sequence database","volume":"21","author":"Kuiken","year":"2005","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jfma.2016.11.014_bib13","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/cid\/ciw349","article-title":"Successful retreatment of HCV in patients coinfected with HIV who failed 12 weeks of ledipasvir\/sofosbuvir","volume":"63","author":"Cooper","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2016.11.014_bib14","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.3390\/v7102876","article-title":"HCV drug resistance challenges in Japan: the role of pre-existing variants and emerging resistant strains in direct acting antiviral therapy","volume":"7","author":"Chayama","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.jfma.2016.11.014_bib15","doi-asserted-by":"crossref","first-page":"e112647","DOI":"10.1371\/journal.pone.0112647","article-title":"A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors","volume":"9","author":"Uchida","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jfma.2016.11.014_bib16","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","author":"AASLD\/IDSA HCV Guidance Panel","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2016.11.014_bib17","first-page":"615A","article-title":"Effect of an IMPDH inhibitor, merimepodib (MMPD), assessed alone or in combination with ribavirin, on HCV replication: implications regarding ribavirin's mechanisms of action","volume":"44","author":"H\u00e9zode","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2016.11.014_bib18","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1128\/JVI.02778-12","article-title":"Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients","volume":"87","author":"Dietz","year":"2013","journal-title":"J Virol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664616304363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664616304363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T15:23:00Z","timestamp":1536160980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664616304363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0929664616304363"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2016.11.014","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2016.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}